Clinical Trial Update: Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating eribulin in combination with anlotinib for metastatic HER2-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Eribulin (eribulin mesilate)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: HER2-negative Breast Cancer | Phase 2 | Status: UNKNOWN